Protease inhibitor use in 233 pregnancies

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 1, 2005, Pages 30-33

  Morris, Anne B ^a   Dobles, Ana Rua ^b   Cu Uvin, Susan ^c   Zorrilla, Carmen ^d   Anderson, Jean ^e   Harwell, Joseph I ^c   Keller, Jean ^e   Garb, Jane ^f  

^a Community Research Initiative of New England ^*  (United States)

^b ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Perinatal transmission; Pregnancy; Protease inhibitors

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHORIOAMNIONITIS; CONTROLLED STUDY; ENDOMETRITIS; FEMALE; FETUS OUTCOME; FETUS WASTAGE; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; LOW BIRTH WEIGHT; LUNG DISEASE; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; NEWBORN; OLIGOHYDRAMNIOS; PANCREATITIS; PLACENTA PREVIA; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SOLUTIO PLACENTAE; UNITED STATES; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLETS; TWINS; VIRAL LOAD;

EID: 24144457513     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000174651.40782.95     Document Type: Article

References (16)

1. Mofenson LM, Lambert JS, Steihm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385-393.
2. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
4. Shapiro D, Tuomala R, Samelson R, et al. Mother to child HIV transmission rates according to antiretroviral therapy, mode of delivery and viral load (PACTG 367). Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28. 2002. Seattle. WA. Abstract 114.
5. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
6. Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306-311.
7. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral in pregnancy: maternal, fetal, and neonatal effects: Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy and the Swiss Neonatal HIV Study. AIDS. 1998;12:F241-F247.
8. Scott G, Shapiro D, Scott W, et al. Safety and tolerance of ritonavir in combination with lamivudine and zidovudine in HIV-1 infected pregnant women and their infants. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract #688.
9. Tuomala RE, Shapiro DE, Mofensen LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
10. Cox DR. Analysis of Binary Data. London: Methuen; 1970:76-99.
11. Lee ET. Statistical Methods for Survival Data Analysis, 2nd ed. New York: John Wiley & Sons; 1992:72-73.
12. Ventura SJ, Martin JA. Taffel SM, et al. Advance report of final natality statistics, 1993. Mon Vital Stat Rep. 1995;44(Suppl):16-17.
13. Cunningham FG, MacDonald PC, Grant NF, et al, eds. Williams Obstetrics. 20th ed. Stamford, CT: Appleton and Lange; 1997.
14. Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville, MD: HIV/AIDS Treatment Information Service. Available at: http://AIDSinfo.nih.gov. Accessed July 8, 2005.
15. Landesman SH, Kalaish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med. 1996;334:1617-1623.
16. Antiretroviral Pregnancy Registry. Wilmington, NC: Pharmaresearch Corp.; 2004. Available at: http://apregistry.com. Accessed July 8, 2005.